Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Osteomark comparable to DEXA:

This article was originally published in Clinica

Executive Summary

Ostex International's bone resorption test Osteomark gave comparable measurements to an existing osteoporosis test, DEXA, in a 653-patient study published in the Journal of Bone and Mineral Research (March 1996). The study found that women with high bone turnover are more likely to lose bone over time, left untreated, than those with low turnover. The data also demonstrated that bone turnover increases prior to the menopause and remains accelerated in post-menopausal years. These findings suggest, say Ostex, that Osteomark could play an effective role in the early assessment of osteoporotic risk in post-menopausal women.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT087756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel